//
Positive recommendation for angiotensin receptor/neprilysin inhibitor: First medication approval for heart failure without "reduced ejection fraction"
Cardiac Implantable Electronic Devices in Patients With Left Ventricular Assist Systems
Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status - Results from the EMPEROR-Reduced Trial
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
Lateral Wall Dysfunction Signals Onset of Progressive Heart Failure in Left Bundle Branch Block
Evaluation and Management of Right-Sided Heart Failure: A Scientific Statement From the American Heart Association
Dapagliflozin for treating chronic heart failure with reduced ejection fraction
Association of Reduced Apical Untwisting With Incident HF in Asymptomatic Patients With HF Risk Factors